Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $CYTK vs $TGTX | Chartloom

Compare

$CYTK vs $TGTX

Cytokinetics Inc · TG Therapeutics Inc

CYTK

Cytokinetics Inc

TGTX

TG Therapeutics Inc

Compare $CYTK vs $TGTX

Comparing Cytokinetics Inc and TG Therapeutics Inc

CYTKCytokinetics Inc

TGTXTG Therapeutics Inc

CYTKCytokinetics Inc

Market cap

$8.35B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

32.92x

Rev growth (TTM)

-21.1%

YTD performance

-0.2%

52W performance

2.6%

FCF yield

-7.0%

TGTXTG Therapeutics Inc

Market cap

$8.32B

P/E (TTM)

19.36x

Forward P/E (NTM)

27.77x

Forward P/S (NTM)

7.37x

Rev growth (TTM)

76.1%

YTD performance

85.6%

52W performance

61.0%

FCF yield

0.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CYTK

TGTX

Detailed metrics comparison

CYTK

Cytokinetics Inc

TGTX

TG Therapeutics Inc

Market Cap

CYTK$8.35B

TGTX$8.32B

Enterprise Value

CYTK$9.25B

TGTX$8.58B

Price

CYTK$61.62

TGTX$54.34

P/E Ratio

CYTKN/A

TGTX19.36x

P/S Ratio

CYTK123.46x

TGTX10.40x

EV/Sales

CYTK136.64x

TGTX10.73x

EV/EBITDA

CYTK1,148.72x

TGTX61.91x

P/B Ratio

CYTK80.24x

TGTX14.03x

P/FCF Ratio

CYTKN/A

TGTX478.48x

EV/FCF

CYTK-15.92x

TGTX493.60x

PEG Ratio

CYTKN/A

TGTX0.83x

Forward P/E (NTM)

CYTKN/A

TGTX27.77x

Forward P/S (NTM)

CYTK32.92x

TGTX7.37x

Revenue (TTM)

CYTK$68M

TGTX$800M

Revenue Growth (YoY)

CYTK-21.1%

TGTX76.1%

Forward Rev Growth

CYTK183.7%

TGTX35.6%

Gross Margin (TTM)

CYTK58.9%

TGTX82.4%

Operating Margin (TTM)

CYTK0.0%

TGTX15.9%

EBITDA Margin (TTM)

CYTK-1027.6%

TGTX17.1%

Net Margin (TTM)

CYTK-1321.1%

TGTX55.2%

FCF Margin (TTM)

CYTK-858.2%

TGTX2.2%

Net Income (TTM)

CYTK$-894M

TGTX$441M

FCF (TTM)

CYTK$-581M

TGTX$17M

EPS (TTM)

CYTK-$6.77

TGTX$2.81

ROE (TTM)

CYTK-13119.0%

TGTX72.3%

ROA (TTM)

CYTK-5902.0%

TGTX33.6%

ROIC (TTM)

CYTK-1872.0%

TGTX39.9%

Cash

CYTK$255M

TGTX$483M

Debt

CYTK$1.15B

TGTX$745M

Net Cash/Debt

CYTK$-892M

TGTX$-263M

Current Ratio (TTM)

CYTK6.66x

TGTX4.27x

Quick Ratio (TTM)

CYTK6.56x

TGTX3.72x

Debt/Equity (TTM)

CYTK6.01x

TGTX1.23x

Debt/Assets (TTM)

CYTK0.0%

TGTX0.0%

Interest Coverage (TTM)

CYTKN/A

TGTXN/A

Net Debt/EBITDA (TTM)

CYTK0.00x

TGTX0.00x

Beta

CYTK0.41

TGTX1.82

52W Performance

CYTK2.6%

TGTX61.0%

YTD Performance

CYTK-0.2%

TGTX85.6%

% from 52W High

CYTK-30.2%

TGTX-8.4%

% from 52W Low

CYTK13.5%

TGTX103.1%

Asset Turnover (TTM)

CYTK0.04x

TGTX0.61x

FCF Yield (TTM)

CYTK-7.0%

TGTX0.2%

Earnings Yield (TTM)

CYTK-10.7%

TGTX5.3%

Dividend Yield (TTM)

CYTKN/A

TGTXN/A

Rule of 40

CYTK-879.2

TGTX78.3

EV/GP/RG

CYTK0.71

TGTX0.31

Ticker research

View CYTK research View TGTX research

Metric	CYTK Cytokinetics Inc	TGTX TG Therapeutics Inc
Market & Valuation
Market Cap	$8.35B	$8.32B
Enterprise Value	$9.25B	$8.58B
Price	$61.62	$54.34
P/E Ratio	N/A	19.36x
P/S Ratio	123.46x	10.40x
EV/Sales	136.64x	10.73x
EV/EBITDA	1,148.72x	61.91x
P/B Ratio	80.24x	14.03x
P/FCF Ratio	N/A	478.48x
EV/FCF	-15.92x	493.60x
PEG Ratio	N/A	0.83x
Forward P/E (NTM)	N/A	27.77x
Forward P/S (NTM)	32.92x	7.37x
Revenue & Growth
Revenue (TTM)	$68M	$800M
Revenue Growth (YoY)	-21.1%	76.1%
Forward Rev Growth	183.7%	35.6%
Profitability
Gross Margin (TTM)	58.9%	82.4%
Operating Margin (TTM)	0.0%	15.9%
EBITDA Margin (TTM)	-1027.6%	17.1%
Net Margin (TTM)	-1321.1%	55.2%
FCF Margin (TTM)	-858.2%	2.2%
Net Income (TTM)	$-894M	$441M
FCF (TTM)	$-581M	$17M
EPS (TTM)	-$6.77	$2.81
ROE (TTM)	-13119.0%	72.3%
ROA (TTM)	-5902.0%	33.6%
ROIC (TTM)	-1872.0%	39.9%
Financial Health
Cash	$255M	$483M
Debt	$1.15B	$745M
Net Cash/Debt	$-892M	$-263M
Current Ratio (TTM)	6.66x	4.27x
Quick Ratio (TTM)	6.56x	3.72x
Debt/Equity (TTM)	6.01x	1.23x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.41	1.82
52W Performance	2.6%	61.0%
YTD Performance	-0.2%	85.6%
% from 52W High	-30.2%	-8.4%
% from 52W Low	13.5%	103.1%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.61x
FCF Yield (TTM)	-7.0%	0.2%
Earnings Yield (TTM)	-10.7%	5.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-879.2	78.3
EV/GP/RG	0.71	0.31
Ticker research	View CYTK research	View TGTX research

Valuation

P/E Ratio

TGTX

19.36x

P/S Ratio

TGTX

10.40x

CYTK

123.46x

EV/FCF

CYTK

-15.92x

TGTX

493.60x

Growth & revenue

Revenue Growth TTM

TGTX

76.1%

CYTK

-21.1%

Forward Revenue Growth

CYTK

183.7%

TGTX

35.6%

Profitability & performance

Gross Margin

TGTX

82.4%

CYTK

58.9%

ROE

TGTX

72.3%

CYTK

-13119.0%

FCF Yield %

TGTX

0.2%

CYTK

-7.0%

52-Week Performance

TGTX

61.0%

CYTK

2.6%

Detailed metrics comparison

CYTK

Cytokinetics Inc

TGTX

TG Therapeutics Inc

Market Cap

CYTK$8.35B

TGTX$8.32B

Enterprise Value

CYTK$9.25B

TGTX$8.58B

Price

CYTK$61.62

TGTX$54.34

P/E Ratio

CYTKN/A

TGTX19.36x

P/S Ratio

CYTK123.46x

TGTX10.40x

EV/Sales

CYTK136.64x

TGTX10.73x

EV/EBITDA

CYTK1,148.72x

TGTX61.91x

P/B Ratio

CYTK80.24x

TGTX14.03x

P/FCF Ratio

CYTKN/A

TGTX478.48x

EV/FCF

CYTK-15.92x

TGTX493.60x

PEG Ratio

CYTKN/A

TGTX0.83x

Forward P/E (NTM)

CYTKN/A

TGTX27.77x

Forward P/S (NTM)

CYTK32.92x

TGTX7.37x

Revenue (TTM)

CYTK$68M

TGTX$800M

Revenue Growth (YoY)

CYTK-21.1%

TGTX76.1%

Forward Rev Growth

CYTK183.7%

TGTX35.6%

Gross Margin (TTM)

CYTK58.9%

TGTX82.4%

Operating Margin (TTM)

CYTK0.0%

TGTX15.9%

EBITDA Margin (TTM)

CYTK-1027.6%

TGTX17.1%

Net Margin (TTM)

CYTK-1321.1%

TGTX55.2%

FCF Margin (TTM)

CYTK-858.2%

TGTX2.2%

Net Income (TTM)

CYTK$-894M

TGTX$441M

FCF (TTM)

CYTK$-581M

TGTX$17M

EPS (TTM)

CYTK-$6.77

TGTX$2.81

ROE (TTM)

CYTK-13119.0%

TGTX72.3%

ROA (TTM)

CYTK-5902.0%

TGTX33.6%

ROIC (TTM)

CYTK-1872.0%

TGTX39.9%

Cash

CYTK$255M

TGTX$483M

Debt

CYTK$1.15B

TGTX$745M

Net Cash/Debt

CYTK$-892M

TGTX$-263M

Current Ratio (TTM)

CYTK6.66x

TGTX4.27x

Quick Ratio (TTM)

CYTK6.56x

TGTX3.72x

Debt/Equity (TTM)

CYTK6.01x

TGTX1.23x

Debt/Assets (TTM)

CYTK0.0%

TGTX0.0%

Interest Coverage (TTM)

CYTKN/A

TGTXN/A

Net Debt/EBITDA (TTM)

CYTK0.00x

TGTX0.00x

Beta

CYTK0.41

TGTX1.82

52W Performance

CYTK2.6%

TGTX61.0%

YTD Performance

CYTK-0.2%

TGTX85.6%

% from 52W High

CYTK-30.2%

TGTX-8.4%

% from 52W Low

CYTK13.5%

TGTX103.1%

Asset Turnover (TTM)

CYTK0.04x

TGTX0.61x

FCF Yield (TTM)

CYTK-7.0%

TGTX0.2%

Earnings Yield (TTM)

CYTK-10.7%

TGTX5.3%

Dividend Yield (TTM)

CYTKN/A

TGTXN/A

Rule of 40

CYTK-879.2

TGTX78.3

EV/GP/RG

CYTK0.71

TGTX0.31

Ticker research

View CYTK research View TGTX research

Metric	CYTK Cytokinetics Inc	TGTX TG Therapeutics Inc
Market & Valuation
Market Cap	$8.35B	$8.32B
Enterprise Value	$9.25B	$8.58B
Price	$61.62	$54.34
P/E Ratio	N/A	19.36x
P/S Ratio	123.46x	10.40x
EV/Sales	136.64x	10.73x
EV/EBITDA	1,148.72x	61.91x
P/B Ratio	80.24x	14.03x
P/FCF Ratio	N/A	478.48x
EV/FCF	-15.92x	493.60x
PEG Ratio	N/A	0.83x
Forward P/E (NTM)	N/A	27.77x
Forward P/S (NTM)	32.92x	7.37x
Revenue & Growth
Revenue (TTM)	$68M	$800M
Revenue Growth (YoY)	-21.1%	76.1%
Forward Rev Growth	183.7%	35.6%
Profitability
Gross Margin (TTM)	58.9%	82.4%
Operating Margin (TTM)	0.0%	15.9%
EBITDA Margin (TTM)	-1027.6%	17.1%
Net Margin (TTM)	-1321.1%	55.2%
FCF Margin (TTM)	-858.2%	2.2%
Net Income (TTM)	$-894M	$441M
FCF (TTM)	$-581M	$17M
EPS (TTM)	-$6.77	$2.81
ROE (TTM)	-13119.0%	72.3%
ROA (TTM)	-5902.0%	33.6%
ROIC (TTM)	-1872.0%	39.9%
Financial Health
Cash	$255M	$483M
Debt	$1.15B	$745M
Net Cash/Debt	$-892M	$-263M
Current Ratio (TTM)	6.66x	4.27x
Quick Ratio (TTM)	6.56x	3.72x
Debt/Equity (TTM)	6.01x	1.23x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.41	1.82
52W Performance	2.6%	61.0%
YTD Performance	-0.2%	85.6%
% from 52W High	-30.2%	-8.4%
% from 52W Low	13.5%	103.1%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.61x
FCF Yield (TTM)	-7.0%	0.2%
Earnings Yield (TTM)	-10.7%	5.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-879.2	78.3
EV/GP/RG	0.71	0.31
Ticker research	View CYTK research	View TGTX research